Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Umbilical Cord-derived Mesenchymal Stromal Cell Injection in Acute Ischemic Stroke
NCT07628933Phase 1Not yet recruiting
- Sponsor
- BOE Technology Group
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke (9 arms), sponsored by BOE Technology Group. Primary endpoints: Incidence of Dose-Limiting Toxicity events at 28 days, All adverse events/serious adverse events during the trial at 2 years and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07628933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07628933.